{"disease":{"id":"uncomplicated-malaria","name":"uncomplicated malaria"},"drugs":{"marketed":[{"drug_id":"hydroxychloroquine","indication_name":"Uncomplicated malaria treatment","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hydroxychloroquine Sulfate","generic_name":"HYDROXYCHLOROQUINE","company_name":"Advanz","drug_phase":"marketed","molecular_target":"Toll-like receptor 9","drug_class":"Antimalarial","quality_score":75,"revenue":null,"mechanism":"Hydroxychloroquine Sulfate works by interfering with the replication of malaria parasites and reducing inflammation in the body."},{"drug_id":"atovaquone-and-proguanil","indication_name":"Treatment of acute, uncomplicated P. falciparum malaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Atovaquone and Proguanil","company_name":"State University of New York - Upstate Medical University","drug_phase":"marketed","molecular_target":"","drug_class":"Antimalarial [EPC]","quality_score":40,"revenue":null,"mechanism":null},{"drug_id":"artesunate-amodiaquine-as-aq","indication_name":"Treatment of acute, uncomplicated Plasmodium falciparum malaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"artesunate-amodiaquine (AS-AQ)","company_name":"Yale University","drug_phase":"marketed","molecular_target":"Plasmodium falciparum heme iron (Fe2+), parasite DNA, heme polymerase","drug_class":"Artemisinin derivative + aminoquinoline antimalarial combination","quality_score":22,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":3,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05842954","title":"Efficacy, Safety and Tolerability of KLU156 in Adults and Children With Uncomplicated P. Falciparum Malaria","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1720,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT05951595","title":"A Study to Find Out if a Combination of 3 Medicines for the Treatment of Malaria Works as Well and is as Safe and Tolerable as Combinations of 2 Medicines","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":1680,"lead_sponsor_name":"University of Oxford","has_results":false},{"nct_id":"NCT06076213","title":"Test Efficacy Study on the Recommended Antimalarial Drugs in the Democratic Republic of the Congo","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":1260,"lead_sponsor_name":"Ministry of Public Health, Democratic Republic of the Congo","has_results":false},{"nct_id":"NCT04767217","title":"Malaria Therapeutic Efficacy Study, Rwanda","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":528,"lead_sponsor_name":"Jhpiego","has_results":false},{"nct_id":"NCT03167242","title":"Efficacy and Safety of KAF156 in Combination With LUM-SDF in Adults and Children With Uncomplicated Plasmodium Falciparum Malaria","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":524,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT06064591","title":"Host Immune and Metabolic Determinants of Sexual Conversion in Plasmodium Parasites IMMETASEX","phase":"","overall_status":"COMPLETED","enrollment_count":458,"lead_sponsor_name":"Institute of Tropical Medicine, Belgium","has_results":false},{"nct_id":"NCT04767191","title":"Malaria Therapeutic Efficacy Study (TES) Kenya","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":400,"lead_sponsor_name":"Jhpiego","has_results":false},{"nct_id":"NCT05764746","title":"Triple Artemisinin-based Combination Therapy for Delaying Drug Resistance Development - a Randomized Clinical Trial","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":384,"lead_sponsor_name":"Muhimbili University of Health and Allied Sciences","has_results":false},{"nct_id":"NCT06300970","title":"Efficacy of Artesunate-amodiaquine and Artemether-lumefantrine for Treatment of Plasmodium Falciparum Malaria in Liberia","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":352,"lead_sponsor_name":"Centers for Disease Control and Prevention","has_results":false},{"nct_id":"NCT03431714","title":"Efficacy and Safety of ASAQ and PD for the Treatment of Uncomplicated Falciparum Malaria in Mainland Tanzania","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":333,"lead_sponsor_name":"National Institute for Medical Research, Tanzania","has_results":false},{"nct_id":"NCT05750628","title":"Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Patients With Uncomplicated Plasmodium Falciparum Malaria","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":327,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT03453840","title":"Extended Duration Artemether-lumefantrine Treatment for Malaria in Children","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":305,"lead_sponsor_name":"University of California, San Francisco","has_results":true},{"nct_id":"NCT04546633","title":"Efficacy, Safety and Tolerability of KAF156 in Combination With Lumefantrine Solid Dispersion Formulation (LUM-SDF) in Pediatric Population With Uncomplicated Plasmodium Falciparum Malaria","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":295,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT05192265","title":"Efficacy and Safety of Pyronaridine-Artesunate Versus Artemether-Lumefantrine","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":172,"lead_sponsor_name":"University of Ibadan","has_results":false},{"nct_id":"NCT07235033","title":"Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort B2)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT07235020","title":"Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":52,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT06036030","title":"Combination Momordica Charantia Extract and Primaquine Againts Plasmodium Falciparum Uncomplicated and Plasmodium Vivax Uncomplicated Treatment in Manokwari, West Papua","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":50,"lead_sponsor_name":"Syamsudin Abdillah,Ph.D, Pharm D","has_results":false},{"nct_id":"NCT05911828","title":"A Study to Determine Safety, Tolerability, and Pharmacokinetics of Different Orally Administered Regimens of the Combination ZY19489-Ferroquine in Adult Asymptomatic Plasmodium Falciparum Carriers","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":36,"lead_sponsor_name":"Zydus Lifesciences Limited","has_results":false}],"total":18},"guidelines":[],"source":"Drug Landscape verified database"}